STAT+: Prometheus raises $12 billion in capital for artificial engineers

Article excerpt

Prometheus secured $12 billion to develop what it calls "artificial general engineers," marking another major capital influx into AI-driven biotech. The funding reflects growing investor appetite for machine-learning applications in drug development and clinical operations. Meanwhile, Abridge announced partnerships with Eli Lilly and Nvidia to streamline clinical trial recruitment using AI tools. In a separate development, a nonprofit acquired a shelved pediatric leukemia drug with plans to distribute it at no cost, a stark contrast to the headline-grabbing venture rounds dominating biotech fundraising.